+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
4 Aug 2015

AstraZeneca & Isis Pharmaceuticals partnership to discover and develop antisense drugs

About the strategic collaboration:

AstraZeneca and Isis Pharmaceuticals, Inc. announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca’s strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney.

AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each programme that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each programme.

About Antisense drugs :

Antisense drugs are short, chemically-modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production by targeting RNA to either prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins.


Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests